Regeneron Pharmaceuticals REGN Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | 24.3%-0.6pp | 24.9%-0.9pp | 25.9%-1.1pp | 27%-0.2pp | 27.2%-0.9pp | |
| Net margin | 29.6%-1.8pp | 31.4%-0.7pp | 32.1%+0.8pp | 31.4%-0.6pp | 31.9%+0.9pp | |
| Returns | ||||||
| Return on equity | 14.5%-0.3pp | 14.9%-0.3pp | 15.2%-0.1pp | 15.3%-0.6pp | 16%0.0pp | |
| Return on invested capital | 10.3%+0.2pp | 10.1%-0.6pp | 10.7%-1.1pp | 11.8%-0.5pp | 12.3%-0.9pp | |
| Efficiency | ||||||
| Asset turnover | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | |
| Liquidity | ||||||
| Current ratio | 3.6×-0.6× | 4.1×+0.1× | 4.1×-0.5× | 4.6×-0.3× | 4.9×+0.2× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Net debt / EBITDA | -0.1×0.0× | -0×-0.1× | 0×-0.1× | 0.2×+0.2× | -0.1×-0.2× | |
| Per Share | ||||||
| Book value per share | $291.77+1.4% | $287.82-0.3% | $288.79+4.8% | $275.68+4.3% | $264.28+3.6% | |
| Valuation | ||||||
| Market capitalization | $81.68B+0.7% | $81.12B+36.1% | $59.59B+5.7% | $56.39B-18.7% | $69.34B-11.4% | |
| Price / earnings | 18.5×+0.5× | 18×+5.0× | 13×+0.4× | 12.6×-2.8× | 15.4×-2.3× | |
| Price / sales | 5.5×-0.2× | 5.7×+1.5× | 4.2×+0.2× | 4×-1.0× | 4.9×-0.6× | |
| Price / book | 2.6×0.0× | 2.6×+0.7× | 1.9×0.0× | 1.9×-0.5× | 2.4×-0.3× | |
| EV / EBITDA | 19.5×-0.1× | 19.6×+5.5× | 14.2×+1.1× | 13.1×-2.8× | 15.9×-1.7× | |
| Dividend yield | 0.5%0.0pp | 0.5%0.0pp | 0.5%+0.1pp | 0.3%+0.2pp | 0.1%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Regeneron Pharmaceuticals's profit margins?
- Regeneron Pharmaceuticals (REGN) runs a 93.9% gross margin and a 24.3% operating margin, with a 29.6% net margin.
- Where do Regeneron Pharmaceuticals's ratios come from?
- Every ratio is computed from Regeneron Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
